Dynavax Technologies Corporation $DVAX Stock Holdings Reduced by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 12.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 482,247 shares of the biopharmaceutical company’s stock after selling 71,315 shares during the quarter. Principal Financial Group Inc.’s holdings in Dynavax Technologies were worth $4,789,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. AlphaQuest LLC increased its position in shares of Dynavax Technologies by 109.9% during the 3rd quarter. AlphaQuest LLC now owns 173,140 shares of the biopharmaceutical company’s stock worth $1,719,000 after purchasing an additional 90,641 shares in the last quarter. Capital Fund Management S.A. bought a new stake in Dynavax Technologies during the second quarter worth about $1,669,000. Exchange Traded Concepts LLC raised its stake in shares of Dynavax Technologies by 50.4% in the third quarter. Exchange Traded Concepts LLC now owns 200,976 shares of the biopharmaceutical company’s stock valued at $1,996,000 after acquiring an additional 67,375 shares during the last quarter. Pacer Advisors Inc. grew its position in Dynavax Technologies by 3,639.9% during the 3rd quarter. Pacer Advisors Inc. now owns 322,119 shares of the biopharmaceutical company’s stock worth $3,199,000 after acquiring an additional 313,506 shares during the last quarter. Finally, Hudson Bay Capital Management LP grew its position in Dynavax Technologies by 46.4% during the 2nd quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock worth $5,373,000 after acquiring an additional 171,700 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on DVAX. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Finally, Wall Street Zen upgraded shares of Dynavax Technologies to a “strong-buy” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.33.

Insider Buying and Selling

In other news, COO David F. Novack sold 114,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the transaction, the chief operating officer owned 63,344 shares of the company’s stock, valued at approximately $990,700.16. This trade represents a 64.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.98% of the stock is currently owned by insiders.

Dynavax Technologies Stock Performance

DVAX stock opened at $15.50 on Monday. The company has a market cap of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. Dynavax Technologies Corporation has a twelve month low of $9.20 and a twelve month high of $15.73. The company has a quick ratio of 6.94, a current ratio of 7.62 and a debt-to-equity ratio of 0.41. The business has a fifty day moving average of $14.40 and a 200-day moving average of $11.82.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.